Allogene Therapeutics ALLO Available-for-Sale Debt Securities - Amortized Cost
Available-for-Sale Debt Securities - Amortized Cost at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's available-for-sale debt securities - amortized cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's available-for-sale debt securities - amortized cost?
- Allogene Therapeutics (ALLO) reported available-for-sale debt securities - amortized cost of $261.82M in Q1 2026.
- How has Allogene Therapeutics's available-for-sale debt securities - amortized cost changed year-over-year?
- Allogene Therapeutics's available-for-sale debt securities - amortized cost decreased by 20.9% year-over-year, from $331.19M to $261.82M.
- What is the long-term trend for Allogene Therapeutics's available-for-sale debt securities - amortized cost?
- Over 5 years (2020 to 2025), Allogene Therapeutics's available-for-sale debt securities - amortized cost has grown at a -23.1% compound annual growth rate (CAGR), from $950.1M to $254.87M.
- What does available-for-sale debt securities - amortized cost mean?
- This is the cost basis of debt securities classified as available-for-sale, adjusted for amortization of premiums or discounts. It represents the value of the investment portfolio before accounting for current market price fluctuations. This provides a baseline for evaluating the performance of the company's liquid investment strategy.